About Cynapsus Therapeutics
Cynapsus Therapeutics is a company based in Toronto (Canada) founded in 2004 was acquired by Sunovion in August 2016. Cynapsus Therapeutics has raised $25.06 million across 6 funding rounds from investors including Orbimed, Sunovion and Aisling Capital. Cynapsus Therapeutics offers products and services including APL-130277.
- Headquarter Toronto, Canada
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cynapsus Therapeutics Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cynapsus Therapeutics
Cynapsus Therapeutics offers a comprehensive portfolio of products and services, including APL-130277.
Sublingual thin film for on-demand management of Parkinson's OFF episodes.
Funding Insights of Cynapsus Therapeutics
Cynapsus Therapeutics has successfully raised a total of $25.06M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $16.75 million completed in April 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cynapsus Therapeutics
Cynapsus Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Sunovion and Aisling Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked |
Investor details for Cynapsus Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cynapsus Therapeutics
Investment portfolio details for Cynapsus Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cynapsus Therapeutics
Detailed financials for Cynapsus Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cynapsus Therapeutics Comparisons
Peer comparison for Cynapsus Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cynapsus Therapeutics
Detailed competitors of Cynapsus Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cynapsus Therapeutics
Complete news archive for Cynapsus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cynapsus Therapeutics
Cynapsus Therapeutics was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Cynapsus Therapeutics is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Cynapsus Therapeutics is a funded company, having raised a total of $25.06M across 6 funding rounds to date.
Cynapsus Therapeutics was founded in 2004 in Toronto, Canada, within the biotechnology sector. Focus is placed on developing a sublingual thin film formulation of apomorphine hydrochloride, known as APL-130277, for managing OFF episodes in advanced Parkinsons disease patients. A Phase 2 clinical trial for this product candidate has been successfully completed. Operations center on CNS disorder treatments, with apomorphine currently approved only as a subcutaneous injection in the United States.
Cynapsus Therapeutics offers APL-130277.
Cynapsus Therapeutics has 4 investors. Key investors include Orbimed, Sunovion, Aisling Capital, and Venrock.